SFA Therapeutics, Inc.
SFA Therapeutics is a clinical-stage biotechnology company focused on developing innovative drugs derived from microbiome-derived metabolites to treat autoimmune, inflammatory, and cancer-related diseases. Their platform technology targets specific diseases with disease-specific drugs, emphasizing safety, efficacy, and predictability. The company is backed by venture capital and is engaged in multiple clinical trials, including treatments for psoriasis, hepatitis B, and liver diseases. Their mission is to change medicine by addressing root causes of diseases and restoring health through microbiome-based therapeutics.
Industries
Nr. of Employees
small (1-50)
SFA Therapeutics, Inc.
Jenkintown, Pennsylvania, United States, North America
Products
Oral small-molecule immunomodulator candidate (psoriasis program)
Orally administered small-molecule immunomodulator developed from microbiome-derived metabolites; demonstrated preclinical efficacy in psoriasis models and evaluated in an early-phase clinical trial for mild-to-moderate plaque psoriasis.
Microbiome-derived small-molecule program for liver disease and cancer prevention
Therapeutic program derived from microbial metabolites aimed at preventing progression of hepatitis B to hepatocellular carcinoma and treating chronic liver diseases including NASH/MASH and fibrosis; supported by issued patents and translational studies in transgenic animal models.
Oral small-molecule immunomodulator candidate (psoriasis program)
Orally administered small-molecule immunomodulator developed from microbiome-derived metabolites; demonstrated preclinical efficacy in psoriasis models and evaluated in an early-phase clinical trial for mild-to-moderate plaque psoriasis.
Microbiome-derived small-molecule program for liver disease and cancer prevention
Therapeutic program derived from microbial metabolites aimed at preventing progression of hepatitis B to hepatocellular carcinoma and treating chronic liver diseases including NASH/MASH and fibrosis; supported by issued patents and translational studies in transgenic animal models.
Expertise Areas
- Microbiome-derived small-molecule drug discovery
- Medicinal chemistry for endogenous metabolite optimization
- Immunomodulation and inflammation therapeutics
- Preclinical efficacy modeling (animal and ex vivo human tissue)
Key Technologies
- Microbiome-derived small molecules
- Medicinal chemistry for small-molecule optimization
- Oral drug formulation technologies
- Disease-relevant animal models (including imiquimod model and transgenic models)